Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Spark's Luxturna Approval Ushers In A New Gene Therapy Era

Dec 19 2017

• By Jessica Merrill

Airliner in flight

Related Content

Novartis Stockpiling Priority Review Vouchers

Dec 19 2017

Spark Stands By $1M Or More Price Possibility For Luxturna

Nov 07 2017

$1M For Luxturna? ICER Says Big Discount Needed To Be Cost Effective

Nov 15 2017

Spark's Gene Therapy Is On The Cusp Of Approval; Now It Gets Interesting

Oct 13 2017

Spark Plots Rebound For Hemophilia A Gene Therapy, As Rival BioMarin Surges

Dec 12 2017

An ASH That Moves The Ball – And The Ticker Price

Dec 11 2017

Mortgage-Style Payments For High-Cost Drugs Left On Cutting-Room Floor

Dec 19 2017

Related Companies

Spark Therapeutics, Inc.

Novartis AG

Kite Pharma, Inc.

Gilead Sciences, Inc.

Novartis AG

Ultragenyx Pharmaceutical Inc.

Additional Topics

Approvals Rare Diseases Pricing Strategies Regulation Commercial BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window